Arecor Therapeutics PLC
Company Profile
Business description
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, Germany, Italy, the Rest of Europe, the USA, and India, out of which the majority is from the UK.
Contact
Chesterford Research Park
Little Chesterford
Saffron WaldenCB10 1XL
GBRT: +44 1223426060
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
44
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
stocks
Is the market still overlooking Alibaba’s AI potential?
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,212.10 | 63.00 | 0.69% |
| CAC 40 | 7,870.34 | 65.37 | 0.84% |
| DAX 40 | 24,377.50 | 191.91 | 0.79% |
| Dow JONES (US) | 44,911.26 | 11.01 | -0.02% |
| FTSE 100 | 9,180.98 | 3.74 | 0.04% |
| HKSE | 25,262.02 | 257.30 | -1.01% |
| NASDAQ | 21,710.67 | 2.47 | -0.01% |
| Nikkei 225 | 43,378.31 | 729.05 | 1.71% |
| NZX 50 Index | 12,889.38 | 55.30 | 0.43% |
| S&P 500 | 6,468.54 | 1.96 | 0.03% |
| S&P/ASX 200 | 8,938.60 | 64.80 | 0.73% |
| SSE Composite Index | 3,700.23 | 33.79 | 0.92% |